摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1,2,4-triazole-3-carboxylate | 39925-12-7

中文名称
——
中文别名
——
英文名称
methyl 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1,2,4-triazole-3-carboxylate
英文别名
methyl 1-(2',3',3''-tri-O-benzoyl-apio-β-D-furanosyl)triazole-3-carboxylate;1-(tri-O-benzoyl-β-D-ribofuranosyl)-1H-[1,2,4]triazole-3-carboxylic acid methyl ester;1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1,2,4-triazole-3-carboxylic acid methyl ester;1-(2,3,5-tri-O-benzoyl-beta-D-ribofuranosyl)-1,2,4-triazole-3-carboxylic acid methyl ester;methyl 1-[(2R,3R,4R,5R)-3,4-dibenzoyloxy-5-(benzoyloxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxylate
methyl 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1,2,4-triazole-3-carboxylate化学式
CAS
39925-12-7
化学式
C30H25N3O9
mdl
——
分子量
571.543
InChiKey
PUHIETBGRWTVIS-PMHJDTQVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    729.0±70.0 °C(Predicted)
  • 密度:
    1.38±0.1 g/cm3(Predicted)
  • 溶解度:
    溶于氯仿、二氯甲烷、乙酸乙酯、

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    42
  • 可旋转键数:
    13
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    145
  • 氢给体数:
    0
  • 氢受体数:
    11

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    methyl 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1,2,4-triazole-3-carboxylate 作用下, 以 甲醇 为溶剂, 反应 24.0h, 以80%的产率得到利巴韦林
    参考文献:
    名称:
    噻唑-4-羧酰胺和1,2,4-三唑-3-羧酰胺的新型Apio核苷的合成及生物学评估
    摘要:
    鉴于吡咯核苷和apio-dideoxy核苷的生物活性,使用2,3-O-异亚丙基-apio-β-d-呋喃糖合成了具有噻唑和三唑碱基部分的新型apio核苷类似物(1和2),它是由d-甘露糖制成的。
    DOI:
    10.1081/ncn-120037666
  • 作为产物:
    描述:
    methyl 3'-O-benzoyl-2,3-O-isopropylidene-β-D-apiofuranoside 在 吡啶4-二甲氨基吡啶 、 ammonium sulfate 、 Dowex 50H+硫酸溶剂黄146六甲基二硅氮烷 作用下, 以 甲醇 为溶剂, 反应 82.5h, 生成 methyl 1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-1,2,4-triazole-3-carboxylate
    参考文献:
    名称:
    噻唑-4-羧酰胺和1,2,4-三唑-3-羧酰胺的新型Apio核苷的合成及生物学评估
    摘要:
    鉴于吡咯核苷和apio-dideoxy核苷的生物活性,使用2,3-O-异亚丙基-apio-β-d-呋喃糖合成了具有噻唑和三唑碱基部分的新型apio核苷类似物(1和2),它是由d-甘露糖制成的。
    DOI:
    10.1081/ncn-120037666
点击查看最新优质反应信息

文献信息

  • Processes for preparing beta-D-ribofuranose derivatives
    申请人:——
    公开号:US20030120064A1
    公开(公告)日:2003-06-26
    Provided are a process for preparing &bgr;-D-ribofuranose derivatives, which are useful as an intermediate for the preparation of ribavirin. The process can be performed under a mild condition, in the presence of a catalyst selected from the group consisting of methanesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid.
    提供了一种制备&bgr;-D-核糖衍生物的过程,其作为制备利巴韦林的中间体非常有用。该过程可以在温和条件下,在甲烷磺酸、苯磺酸和对甲苯磺酸等催化剂的存在下进行。
  • 1-(.beta.,-D-ribofuranosyl)-1,2,4-triazole acid esters
    申请人:ICN Pharmaceuticals, Inc.
    公开号:US03984396A1
    公开(公告)日:1976-10-05
    Phosphate and carboxylic acid esters of 1-(.beta.-D-ribofuranosyl)-1,2,4-triazoles are prepared by a variety of methods and their antiviral activity reported.
    1-(β-D-核糖呋喃基)-1,2,4-三唑的磷酸酯和羧酸酯通过多种方法制备,并报告了它们的抗病毒活性。
  • Dendranthema plant named ‘Firedance Igloo’
    申请人:Vandenberg Cornelis P.
    公开号:USPP029835P2
    公开(公告)日:2018-11-13
    A new and distinct cultivar of Dendranthema plant named ‘Firedance Igloo’, characterized by its upright, outwardly spreading and uniformly mounded plant habit; freely branching habit; dense and full plant form; uniform and freely flowering habit; daisy-type inflorescences; bright greyed purple-colored ray florets; natural season flowering occurs about September 17 to 22 in Pennsylvania; and good garden performance and winter hardiness.
    一种新的独特的菊花属植物品种,名为“Firedance Igloo”,其特点是植株直立、向外扩展和均匀成丘状;自由分枝习性;植株形态密集而丰满;均匀自由地开花;菊花状花序;明亮的灰紫色花瓣;在宾夕法尼亚州大约在9月17日至22日左右自然季节开花;具有良好的园艺表现和耐寒性。
  • Processes for preparing &bgr;-D-ribofuranose derivatives
    申请人:Yuhan Corporation
    公开号:US06660854B2
    公开(公告)日:2003-12-09
    Provided are a process for preparing &bgr;-D-ribofuranose derivatives, which are useful as an intermediate for the preparation of ribavirin. The process can be performed under a mild condition, in the presence of a catalyst selected from the group consisting of methanesulfonic acid, benzenesulfonic acid and p-toluenesulfonic acid.
    提供了一种制备&bgr;-D-核糖衍生物的过程,该衍生物可作为制备利巴韦林的中间体。该过程可以在温和条件下,在甲烷磺酸、苯磺酸和对甲苯磺酸等催化剂的存在下进行。
  • Vorbrueggen, Helmut; Krolikiewicz, Konrad; Bennua, Baerbel, Chemische Berichte, 1981, vol. 114, # 4, p. 1234 - 1255
    作者:Vorbrueggen, Helmut、Krolikiewicz, Konrad、Bennua, Baerbel
    DOI:——
    日期:——
查看更多

同类化合物

利巴韦林杂质G 利巴韦林杂质E 利巴韦林杂质B 利巴韦林 利巴韦林 三氮唑核苷脒盐酸盐 三氮唑核苷羧酸 三氮唑核苷5'-氨基磺酸 三氮唑核苷-5'-磷酸酯 三氮唑核苷 5'-二磷酸酯 三氮唑核苷 5'-三磷酸酯 三氮唑核苷 2',3',5'-三乙酸酯 三乙酰利巴韦林甲酯 [5-(3-氨基-1,2,4-三唑-1-基)-3,4-二苯甲酰氧基-四氢呋喃-2-基]甲基苯甲酸酯 [(2R,3S,4R,5R)-5-(3-硫代氨基甲酰-1,2,4-三唑-1-基)-3,4-二羟基四氢呋喃-2-基]甲基氨基磺酸 [(2R,3S,4R,5R)-5-(3-氨基羰基-1,2,4-三唑-1-基)-3,4-二羟基-四氢呋喃-2-基]甲基二氢磷酸酯与N,N-二乙基乙胺的化合物 5-氨基-1-[(2R,3R,4S,5R)-3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]-1,2,4-三唑-3-甲脒盐酸盐 5'-O-吡喃葡萄糖基三氮唑核苷 5'-O-吡喃半乳糖基三氮唑核苷 3-氰基-1-(2,3,5-三-O-乙酰基-beta-D-呋喃核糖基)-1,2,4-三唑 2’,3’-异亚丙基三氮唑核苷 2',3'-异亚丙基α-利巴韦林 2'-脱氧三氮唑核苷 1-Β-D-呋喃核糖基-1H-1,2,4-三氮唑-3-羧酸甲酯 1-[2,3-O-异亚丙基-beta-D-呋喃核糖基]-1,2,4-三唑-3-羧酸甲酯 1-[(2S,3S,4S,5S)-3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]-1,2,4-三唑-3-甲酰胺 1-[(2R,3R,4R,5R)-3,4-二丁氧基-5-(丁氧基甲基)四氢呋喃-2-基]-1,2,4-三唑-3-甲酰胺 1-(2-C-甲基-BETA-D-呋喃核糖基)-1H-1,2,4-三唑-3-甲酰胺 (2R,3S,4R,5R)-2-(羟基甲基)-5-[3-(甲氧基亚胺甲酰基)-1,2,4-三唑-1-基]四氢呋喃-3,4-二醇 (2R,3R,4S,5R)-2-[3-(乙氧基亚胺甲酰基)-1,2,4-三唑-1-基]-5-(羟基甲基)四氢呋喃-3,4-二醇 N1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-C4-(coumarin-7-oxymethyl)-1,2,3-triazole 4,5-dibromo-1-(5-O-sulfamoyl-β-D-ribofuranosyl)triazole (2R,3R,4S,5R)-3'-(2-fluorophenyl)-5-(hydroxymethyl)-4,5-dihydro-3H,4'H,6'H-spiro[furan-2,7'-[1,2,3]triazolo[5,1-c][1,4]oxazine]-3,4-diol 4-((1-(β-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)methoxy)-2-phenylquinazoline ribavirin-5’-O-bis(benzoxy-L-alaninyl)phoshate 1-(5-deoxy-5-N-phosphonomethylamino-β-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide (2R,3R,4S,5R)-3'-(4-chlorophenyl)-5-(hydroxymethyl)-4,5-dihydro-3H,4'H,6'H-spiro[furan-2,7'-[1,2,3]triazolo[5,1-c][1,4]oxazine]-3,4-diol 1-(4'-azido-2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)-4-cyclopropyl-[1,2,3]-triazole 1-(5-O-thiophosphoryl-β-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide 5-[2-(4-chlorophenyl)ethynyl]-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[2-(1-methylimidazol-4-yl)ethynyl]-1,2,4-triazole-3-carboxamide 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[2-[2-(trifluoromethyl)phenyl]ethynyl]-1,2,4-triazole-3-carboxamide 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[2-(4-methylphenyl)ethynyl]-1,2,4-triazole-3-carboxamide 5-(4-trifluoromethylphenylethynyl)-1-(2,3,5-tri-hydroxy-β-D-ribofuranosyl)-1H-[1,2,4]triazole-3-carboxylic acid amide 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(2-phenylethynyl)-1,2,4-triazole-3-carboxamide 5-(5-chloropent-1-ynyl)-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide 5-(3-trifluoromethyl-phenylethynyl)-1-(2,3,5-tri-hydroxy-β-D-ribofuranosyl)-1H-[1,2,4]triazole-3-carboxylic acid amide 5-(thiophen-3-ylethynyl)-1-(2,3,5-tri-hydroxy-β-D-ribofuranosyl)-1H-[1,2,4]triazole-3-carboxylic acid amide 5-(4-methoxyphenylethynyl)-1-(2,3,5-tri-hydroxy-β-D-ribofuranosyl)-1H-[1,2,4]triazole-3-carboxylic acid amide 4-tetradecyloxymethyl-1-(β-D-arabinofuranosyl)-1,2,3-triazole